New Obesity Drug VK2735 Advances to Phase 3 Trials for Oral Formulation

Viking Therapeutics is progressing its experimental obesity drug, VK2735, with plans to initiate Phase 3 trials for an oral tablet formulation later this year. The company is also conducting a Phase 1 study to evaluate maintenance dosing strategies for the injectable formulation, with results expected in the third quarter of 2026.

Context

Viking Therapeutics is a biopharmaceutical company focused on developing therapies for metabolic diseases. VK2735 is an experimental drug aimed at addressing obesity, which affects a substantial portion of the global population. The drug is currently being tested in multiple formulations, including an injectable version.

Why it matters

The advancement of VK2735 to Phase 3 trials represents a significant step in the development of new obesity treatments. Obesity is a growing public health concern, linked to various chronic diseases. Effective oral medications could improve treatment adherence and accessibility for patients.

Implications

If VK2735 proves effective, it could offer a new treatment option for individuals struggling with obesity, potentially impacting millions. Successful trials may lead to regulatory approval, influencing the market for obesity medications. The outcomes may also affect Viking Therapeutics' financial standing and future research directions.

What to watch

The initiation of Phase 3 trials for the oral formulation is expected later this year, which will be a critical milestone for the drug's development. Additionally, results from the Phase 1 study on maintenance dosing for the injectable version are anticipated in the third quarter of 2026. These developments will provide insights into the drug's efficacy and safety.